Literature DB >> 6721574

Sequential studies of gliadin antibodies in patients with dermatitis herpetiformis.

M Kieffer, R S Barnetson, J N Blackwell.   

Abstract

Sequential studies of circulating gliadin antibodies (IgG, IgA, IgM, IgD) were performed in 24 patients with dermatitis herpetiformis (DH) by an ELISA. Three groups of patients were studied: (a) 14 patients who responded to a gluten-free diet and were able to stop their drug therapy, (b) 5 patients who did not respond to a gluten-free diet, (c) 5 patients with normal jejunal biopsies, who did not receive a gluten-free diet. Most of the serum gliadin antibodies detected were of IgG class, but in several patients IgA gliadin antibodies were found in addition. When the patients were on a normal diet, 63% had elevated IgG gliadin antibody titres (titres which exceeded the maximum titre of the controls by one dilution) and there were no significant differences between the three groups. When the patients were followed up, there was a significant fall in the gliadin antibody titres in those who responded to a gluten-free diet compared to the two other groups of patients. Thus assays of IgG gliadin antibodies might be helpful in some patients in judging the compliance of patients on a gluten-free diet.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6721574     DOI: 10.1007/BF00511058

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  14 in total

1.  Food antibodies in patients with dermatitis herpetiformis and adult coeliac disease - relationship to jejunal morphology.

Authors:  P J Kumar; A Ferguson; M Lancaster-Smith; M L Clark
Journal:  Scand J Gastroenterol       Date:  1976       Impact factor: 2.423

2.  Clearance of skin lesions in dermatitis herpetiformis after gluten withdrawal.

Authors:  L Fry; P P Seah; D J Riches; A V Hoffbrand
Journal:  Lancet       Date:  1973-02-10       Impact factor: 79.321

3.  Coeliac syndrome in dermatitis herpetiformis.

Authors:  S Shuster; A J Watson; J Marks
Journal:  Lancet       Date:  1968-05-25       Impact factor: 79.321

4.  Anti-gliadin antibodies and small intestinal mucosal damage in dermatitis herpetiformis.

Authors:  D J Unsworth; J N Leonard; R M McMinn; A F Swain; E J Holborow; L Fry
Journal:  Br J Dermatol       Date:  1981-12       Impact factor: 9.302

5.  Clinical response of dermatitis herpetiformis skin lesions to a gluten-free diet.

Authors:  R C Heading; W D Paterson; D B McClelland; R S Barnetson; M S Murray
Journal:  Br J Dermatol       Date:  1976-05       Impact factor: 9.302

6.  Dermatitis herpetiformis: diagnosis, diet and demography.

Authors:  D J Gawkrodger; J N Blackwell; H M Gilmour; E A Rifkind; R C Heading; R S Barnetson
Journal:  Gut       Date:  1984-02       Impact factor: 23.059

7.  Gluten-free diet for dermatitis herpetiformis: the long-term effect on cutaneous, immunological and jejunal manifestations.

Authors:  T Frödin; R Gotthard; J Hed; L Molin; K Norrby; A Walan
Journal:  Acta Derm Venereol       Date:  1981       Impact factor: 4.437

8.  Defective Fc-receptor functions associated with the HLA-B8/DRw3 haplotype: studies in patients with dermatitis herpetiformis and normal subjects.

Authors:  T J Lawley; R P Hall; A S Fauci; S I Katz; M I Hamburger; M M Frank
Journal:  N Engl J Med       Date:  1981-01-22       Impact factor: 91.245

9.  Lymphoma in dermatitis herpetiformis: report on four cases.

Authors:  T Reunala; H Helin; K Kuokkanen; T Hakala
Journal:  Acta Derm Venereol       Date:  1982       Impact factor: 4.437

10.  Quantitation of intraepithelial lymphocytes in human jejunum.

Authors:  A Ferguson; D Murray
Journal:  Gut       Date:  1971-12       Impact factor: 23.059

View more
  1 in total

1.  Dermatitis herpetiformis: relation between circulating immune complexes, small-intestinal mucosal status, and immunohistopathological findings.

Authors:  E Szabó; S Husz; T Várkonyi; Z F Kiss
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.